Table 1.

Baseline characteristics of treated subjects

		PRO 140
Characteristic	Placebo (n=10)	162mg Weekly (n=11)	324mg Biweekly (n=12)	324mg Weekly (n=11)	All Subjects (n=44)
Age, years	44.9 (32.3–51.6)	40.0 (29.1–44.6)	45.9 (31.0–59.6)	41.1 (34.8–53.6)	42.4 (29.1–59.6)
Sex, male/female (n)	9/1	10/1	11/1	10/1	40/4
Race, black/white (n)	3/7	5/6	5/7	4/7	17/27
Weight, kg	82.3 (59.4–107)	77.0 (59.3–94.4)	88.3 (58.9–102)	69.0 (60.8–83.6)	79.1 (58.9–107)
CD4+ cell count, cells/μL	410 (312–878)	352 (307–611)	493 (357–911)	389 (341–638)	410 (307–911)
HIV-1 RNA, log10 copies/mL	4.09 (3.94–5.13)	4.43 (3.92–4.97)	4.60 (4.03–6.68)	4.19 (3.61–4.77)	4.40 (3.61–6.68)

NOTE: Data are median (range) values unless otherwise indicated.